RareCyte specializes in advanced technologies for Spatial Biology and Liquid Biopsy solutions, providing researchers and clinicians with tools to analyze rare cells and key biomarkers. Their Orion™ platform enables highly multiplexed fluorescent imaging, allowing for in-depth biomarker analysis through a streamlined staining and imaging process. This technology is designed to break barriers in biomarker imaging, offering rapid and comprehensive data collection. Additionally, RareCyte's CyteFinder® imaging system facilitates high-throughput fluorescence imaging and single-cell retrieval, enhancing the identification of rare cells in various biological samples.

In the realm of Liquid Biopsy, RareCyte offers a robust workflow for the detection and analysis of circulating tumor cells (CTCs). Their platform ensures sensitive, accurate, and reproducible results, from blood collection to single-cell isolation. The technology supports the development of custom assays and companion diagnostics, enabling researchers to utilize cancer-specific panels for CTC biomarker analysis. This capability is crucial for monitoring cancer progression, assessing treatment effectiveness, and predicting patient outcomes, thereby contributing significantly to precision medicine and clinical research in oncology.

United States

Leaders across Research, Translational Medicine and the Clinic rely on RareCyte as a one-stop resource for Spatial Biology and Liquid Biopsy solutions.

Headquartered in Seattle, WA, RareCyte is an innovative precision biology company that has developed technologies and end-to-end integrated platforms enabling advances in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy.

Our highly multiplexed fluorescent imaging systems, reagents and contract services empower investigators to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics through rare cell analysis.

RareCyte

Company Details